The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.
News and Features
Vaccine efficacy was 68.4% against RSV-associated acute respiratory disease; offers protection against subtypes A and B.
High-dose recombinant vaccine more effective than egg-based standard-dose vaccine among adults aged 50 to 64.
Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor.
Authors recommend hepatitis C treatment with sofosbuvir-based regimens should be expanded, including to those receiving dialysis.
Estimated probability of maintaining undetectable plasma RNA through 2 years was 33 and 57% in cohorts 1 and 2, respectively.
A total of 5 people have been diagnosed with the illness, and all have recently been in Baja California, Mexico.
The study is being conducted by MATRIX, a program funded by the USAID that focuses on developing new HIV prevention products for women.
Cresemba is an azole antifungal available for injection and in a capsule formulation.
Vaccine effectiveness highest in first year after vaccination and decreases considerably over time.
Polihexanide + propamidine safe, effective against Acanthamoeba keratitis infection.
VT-X7 is a drug/device combination product designed to deliver therapeutic concentrations of 2 broad spectrum antibiotics.
The HIV medications are all manufactured by ViiV Healthcare, a GlaxoSmithKline.
Previously, the ACIP had recommended the vaccine for use only during an outbreak.
Drug is the only medicine approved for use in infants with congenital syphilis.
Incidence of C. difficile infection reduced by 45% with doxycycline among patients with prior history of CDI.
Higher proportion of children aged younger than 5 years living with HIV experience interruptions in treatment.
Opt-in approach with option to request a self-sampling kit minimally increases screening uptake.
Preliminary data on the variant suggest it does not trigger more severe illness than previous variants.